Real-World study tests immunotherapy for aggressive lung cancer
NCT ID NCT07308379
First seen Jan 03, 2026 · Last updated Jun 10, 2026 · Updated 20 times
Summary
This study looks at how well the drug Toripalimab works as the first treatment for people with extensive-stage small cell lung cancer, a fast-growing lung cancer that has spread. Researchers will track 1,200 patients in China to see how long the cancer stays under control and how long patients live. The goal is to understand the drug's real-world benefits and safety outside of a controlled clinical trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLC, EXTENSIVE STAGE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.